Axial Spondyloarthritis

In our late-breaking abstract coverage, we spoke with Prof. Denis Poddubnyy from Charité-Universitätsmedizin Berlin to discuss key data from EULAR 2024 on axial spondyloarthritis (axSpA). We first explored the open-label extension results of the phase 3 BE MOBILE 2 study (NCT04436640), which assessed bimekizumab's impact on 2-year radiographic progression in the spine of patients with radiographic axSpA. Hypothesized to offer superior inhibition of bone formation due to its dual action on IL-17A and IL-17B, bimekizumab's findings were compared with other treatments like ixekizumab, upadacitinib, secukinumab, and certolizumab pegol, highlighting implications for clinical practice. Additionally, we examined a recent study by Berg et al., which compared remote monitoring and patient-triggered monitoring to traditional face-to-face consultations. The discussion focuses on how these findings could influence daily practice, patient outcomes, and healthcare resource management.

International guidelines emphasize achieving remission or low disease activity in axial spondyloarthritis (axSpA) through a treat-to-target approach. Despite this, choosing the optimal first or second-line treatment remains challenging due to limited comparative data. The Treat-to-Target in Axial Spondyloarthritis (AScalate) trial (NCT03906136) aimed to assess the efficacy of the IL-17 inhibitor secukinumab as a first-line treatment versus standard care. At EULAR 2024, Prof. Denis Poddubnyy presented the study results, offering insights into the trial’s rationale, design, and key findings. This interview explores these aspects and discusses their implications for clinical practice.

Axial spondyloarthritis is a chronic, inflammatory rheumatic disease that affects the axial skeleton, causing severe pain, stiffness and fatigue. touchIMMUNOLOGY were delighted to speak with Dr Fabian Proft (Charité Universitätsmedizin Berlin, Germany) about the treatment paradigm and unmet needs of axial spondyloarthritis. The abstract ‘Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with […]

BE MOBILE 1 and BE MOBILE 2 are double-blind, phase 3 trials designed to evaluate efficacy and safety of bimekizumab, a novel dual interleukin (IL)-17A and IL-17F inhibitor, across the axial spondyloarthritis spectrum. touchIMMUNOLOGY were delighted to speak with Dr Fabian Proft (Charité Universitätsmedizin Berlin, Germany) about these trials and his poster on the maintenance […]